Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;

Slides:

Advertisements

Similar presentations

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.

Advertisements

TREATMENT OF TUBERCULOSIS, 2003

Second-line Anti-TB drugs

Tuberculosis Evaluation in the Underserved Community John W. Wilson, MD Division of Infectious Diseases Mayo Clinic, Rochester.

‘Resistant infections’ Dr Julian Sutton Consultant in Infectious Diseases & Medical Microbiology.

Sheboygan County 2013 Sandy Muesegades, RN – Public Health Nurse.

Clinical Case Female, 27 years of age 3 rd year Internal Medicine resident at the Mexicali General Hospital Never smoked; does not ingest alcoholic beverages.

1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

MICR 454L Emerging and Re-Emerging Infectious Diseases Lecture 7: M. tuberculosis Dr. Nancy McQueen & Dr. Edith Porter.

Diagnosis and Management of TB John Yates Consultant Infectious Diseases.

TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.

Introduction to Tuberculosis

MDR/XDR Tuberculosis and Atypical Mycobacterial Disease MDR/XDR Tuberculosis and Atypical Mycobacterial Disease Increasing Role for Surgery, Relearning.

Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.

Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February Yerevan New treatments and approaches.

Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.

Tuberculosis: What you need to know!

Antimycobacterial drugs By Bohlooli S, PhD School of Medicine, Ardabil University of Medical Sciences.

PRE-EXTENSIVELY DRUG RESISTANT (XDR) TB IN WISCONSIN  Marathon County  Population 134,700  1,545 square miles  Marathon County Health Department 

Management of Tuberculosis (TB) and Multidrug-Resistant TB (MDR TB)

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,

TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.

Copyright (c) 2004 Elsevier Inc. All rights reserved. Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy, and Mycobacterium avium Complex Infections.

Molecular diagnosis of drug resistant tuberculosis by a DNA array

Clinical Case Female, 27 years of age Female, 27 years of age 3 rd year Internal Medicine resident at the Mexicali General Hospital 3 rd year Internal.

MICR 454L Emerging and Re-Emerging Infectious Diseases Lecture 7:

MULTIDRUG- RESISTANT TUBERCULOSIS (MDR-TB) by Dr Mat Zuki Mat Jaeb 1.

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

Ward 5D Linda Iskandar 1. Patient MR From Nepal, has been in Australia for 2 years on a dependent student visa studying nursing. Presenting complaints.

TREATMENT OF TUBERCULOSIS: Prevention: BCG vaccination: It does not prevent infection but limits multiplication and spread of following infection so prevents.

Anti-TB Agents Dr. Jeff Hobden MIP. Mycobacterium tuberculosis TB is hard to kill with antibiotics TB is hard to kill with antibiotics Slow growth Slow.

Tuberculosis. TB is a common infectious disease caused by the bacterium Mycobacterium tuberculosis. The bacteria usually affects the lungs but it can.

Antimycobacterial Drugs

TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.

Volume 124, Issue 6, Pages (December 2003)

Treatment algorithm for tuberculosis

Copyright © 2006 American Medical Association. All rights reserved.

SUSCEPTIBILITY TESTING OF MYCOBACTERIUM KANSASII STRAINS ISOLATED FROM PATIENTS BETWEEN 2000 AND 2015 IN POLAND Zofia Bakuła1, Magdalena Modrzejewska1,

1 Drug susceptible TB Limited resistance MDR-TB (Frieden, 1993) XDR-TB

Figure 1. Brain imaging findings in chronological order: (A) initial brain CT shows negative findings on HD 3; (B) follow-up brain MRI (T2WI, enhanced)

Drug Resistant (DR) TB (Back to Basics)

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm S.O. Simons, T. van der Laan,

اهداف جهاني تعيين شده از سوي WHOبراي كشورها

Marie Turner, M.D. Jo-Ann Keegan, R.N., M.S.N.

مقدمه مایکوباکتریوم توبرکلوزیس متعلق به خانواده مایکوباکتریاسه و راسته آکتینومیتالها و مولد بیماری سل می‌باشد. باسیل‌های سل میله‌ای شکل، بلند و خمیده و.

STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.

HSP65-PRA identification of non-tuberculosis mycobacteria from 4892 samples suspicious for mycobacterial infections M. Saifi, E. Jabbarzadeh, A.R. Bahrmand,

Respiratory System Drugs

Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array W.-L. Huang, Z.-J. Hsu, T.C.

... و خدایی که در این نزدیکیست

Tb: Screening & Diagnosis (1)

Tuberculosis in children BY MBBSPPT.COM

Characterization of Mycobacterium tuberculosis isolated from cancer patients with suspected tuberculosis infection in Egypt: identification, prevalence,

Antimycobacterial Drugs

L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X

Anti Tuberculosis Norah A A AL KHATHLAN MD 4/18/2019 Failure or MDR_TB.

Clarithromycin and amikacin vs

Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview

CASE HOLDING FOR PMDT.

Tuberculosis Control Program

Cerebral Tuberculosis

Treatment of Drug Resistant TB - Questions

DR SAUMU WAYUWA KPA ANNUAL SCIENTIFIC CONFERENCE 2019

Purdue University Pharmacy

Diversity of resistant and susceptible isolates.

Synchronization of a basic diagnostic algorithm (linked diagnostic tests) with different levels of diagnostic services. Synchronization of a basic diagnostic.

Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,

Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.

Presentation transcript:

Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis; PCR, polymerase chain reaction; INH, isoniazid; RFP, rifampin; CXR, chest X ray; IPM, imipenem; LVX, levofloxacin; MXF, moxifloxacin; AMK, amikacin; KAN, kanamycin; EMB, ethambutol; CCS, cycloserine; PTH, prothionamide; DMS, dexamethasone; LZD, linezolid; HD, Hospital day. Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis; PCR, polymerase chain reaction; INH, isoniazid; RFP, rifampin; CXR, chest X ray; IPM, imipenem; LVX, levofloxacin; MXF, moxifloxacin; AMK, amikacin; KAN, kanamycin; EMB, ethambutol; CCS, cycloserine. . . Infect Chemother. 2016 Mar;48(1):41-46. http://dx.doi.org/10.3947/ic.2016.48.1.41